Cargando…
Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
BACKGROUND: Pulmonary hypertension patients experienced a high financial burden due to the high cost of drug therapy, high incidence of comorbidities and hospitalizations. Endothelin receptor antagonists (ERAs) in PAH treatment showed a high cost. While ambrisentan has been covered by medical insura...
Autores principales: | Chen, Jingyuan, Luo, Jun, Yang, Xiaojie, Luo, Peng, Chen, Yusi, Li, Zilu, Li, Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165300/ https://www.ncbi.nlm.nih.gov/pubmed/34079351 http://dx.doi.org/10.2147/IJGM.S304992 |
Ejemplares similares
-
Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018) -
The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022) -
Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022) -
Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022) -
Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)